查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601251

RNA干擾技術市場：按類型、治療方法、應用分類 - 2025-2030 年全球預測

RNA Interference Technology Market by Type (dsRNA, miRNA, siRNA), Therapeutics (Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年RNA干擾技術市場規模為329.2億美元，預計2024年將達392.5億美元，複合年成長率為22.38%，2030年將達1354億美元。

RNA干擾（RNAi）技術是分子生物學中的革命性工具，能夠定序特定基因，為研究基因功能和開發新的治療策略提供了強大的手段。其範圍涵蓋廣泛的領域，包括基礎研究、藥物發現和治療應用，主要關注遺傳性疾病和後天性疾病。 RNAi 的需求在於其精確靶向致病基因的獨特能力，這為癌症、病毒感染疾病、遺傳性疾病等的個人化醫療和治療帶來了希望。最終用途廣泛，包括製藥公司、生技公司和學術研究機構。

主要市場統計
基準年[2023] 329.2億美元
預測年份 [2024] 392.5億美元
預測年份 [2030] 1,354億美元
複合年成長率（%） 22.38%

RNAi 技術的市場成長受到技術進步、慢性病盛行率增加以及對個人化醫療日益成長的興趣的顯著影響。此外，對 RNAi 研發的大量投資以及學術機構和生物技術公司之間的合作正在為技術創新打開新的大門。遞送方法的最新趨勢以及有效和選擇性 siRNA 的開發為臨床應用提供了巨大的機會。雖然北美目前憑藉強大的醫療基礎設施和研究活動處於領先地位，但由於醫療保健投資的增加和政府對基因研究的資助的增加，預計亞太地區將出現顯著成長。

然而，該市場面臨一些限制，包括 RNAi 分子向細胞質的遞送挑戰、潛在的脫靶效應以及提高生物環境穩定性的需要。此外，監管障礙和高昂的開發成本仍然是市場成長和滲透的主要挑戰。專注於增強遞送系統、提高標靶特異性以及利用奈米粒子實現更安全、更有效的 RNAi 遞送的創新是有前景的研究和開發領域。該公司正在投資將 RNAi 與 CRISPR 等其他基因編輯技術相結合，以擴大治療應用，並利用與學術研究機構的合作來加速這個充滿活力的市場的創新和採用。

市場動態：揭示快速發展的RNA干擾技術市場的關鍵市場洞察

RNA干擾技術市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球遺傳疾病和慢性病盛行率上升
    • 擴大RNAi技術在藥物發現與藥物開發的應用
    • 對分子診斷的需求不斷成長
  • 市場限制因素
    • FDA 對 RNAi 治療的嚴格規定
  • 市場機會
    • 奈米技術和癌症領域的持續研究和開發
    • 正在開發的尖端 RNAi 療法
  • 市場挑戰
    • RNA干擾治療實施中的擔憂

波特五力：駕馭RNA干擾科技市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解RNA干擾技術市場的外部影響

外部宏觀環境因素在塑造RNA干擾技術市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解RNA干擾技術市場的競爭狀況

RNA干擾技術市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣RNA干擾技術市場供應商績效評估

FPNV定位矩陣是評估RNA干擾技術市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球遺傳疾病和慢性病的增加
      • 擴大RNAi技術在藥物發現與開發的應用
      • 分子診斷的需求不斷增加
    • 抑制因素
      • FDA 對 RNAi 治療的嚴格規定
    • 機會
      • 奈米技術和癌症領域的持續研究和開發
      • 正在開發的尖端 RNAi 療法
    • 任務
      • 對RNA干擾療法實施的擔憂
  • 市場區隔分析
    • 類型：利用siRNA進行標靶基因治療，治療多種疾病
    • 應用：快速採用RNA干擾技術進行藥物發現與開發
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章RNA干擾技術市場：依類型

  • 雙鏈RNA
  • 微型RNA
  • siRNA

第7章RNA干擾技術市場治療

  • 自體免疫肝炎
  • 乙型肝炎及丙型肝炎
  • 神經系統疾病
  • 腫瘤學
  • 呼吸系統疾病

第8章RNA干擾技術市場：依應用分類

  • 藥物發現與開發
  • 治療藥物

第9章 美洲RNA干擾技術市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太RNA干擾技術市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲RNA干擾技術市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Switch Therapeutics 融資 5,200 萬美元用於開發首個 RNAi 技術
    • Alnylam Pharmaceuticals 和 Medison Pharma 宣布將合作範圍擴大到多地域夥伴關係，以實現 RNAi 療法的商業化

公司名單

  • Gradalis, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Merck KGaA
  • NeuBase Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Bioneer Corporation
  • Ionis Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • AMSBIO
  • Atalanta Therapeutics
  • Phio Pharmaceuticals Corp.
  • Thermo Fisher Scientific Inc.
  • Sanofi SA
  • AstraZeneca PLC
  • Dicerna Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • ProQR Therapeutics NV
  • Silence Therapeutics PLC
  • CureVac NV
  • Alnylam Pharmaceuticals, Inc.
  • Gotham Therapeutics Corp.
Product Code: MRR-0375F3EAA810

The RNA Interference Technology Market was valued at USD 32.92 billion in 2023, expected to reach USD 39.25 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 135.40 billion by 2030.

RNA interference (RNAi) technology is a revolutionary tool in molecular biology that enables the silencing of specific genes, thus providing a powerful means for studying gene function and developing novel therapeutic strategies. Its scope extends across multiple dimensions, including basic research, drug discovery, and therapeutic application, primarily focusing on genetic and acquired diseases. The necessity of RNAi lies in its unique ability to precisely target disease-causing genes, thereby offering promise in personalized medicine and treatment of conditions like cancer, viral infections, and genetic disorders. The tight end-use scope involves pharmaceuticals, biotechnology companies, and academic research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 32.92 billion
Estimated Year [2024] USD 39.25 billion
Forecast Year [2030] USD 135.40 billion
CAGR (%) 22.38%

Market growth for RNAi technology is heavily influenced by technological advancements, increasing incidences of chronic diseases, and the expanding interest in personalized medicine. Additionally, substantial investments in RNAi research and development, along with collaborations between academic institutions and biotech firms, are opening new doors for innovation. Recent advancements in delivery methods and the development of potent and selective siRNAs present significant opportunities in clinical applications. The North American region is currently leading due to robust healthcare infrastructure and research activity, yet Asia-Pacific is expected to witness substantial growth due to rising healthcare investments and increased government funding for genetic research.

However, the market faces several limitations, such as delivery challenges of RNAi molecules into the cell cytoplasm, potential off-target effects, and the necessity for improved stability in biological settings. Furthermore, regulatory hurdles and high development costs remain significant challenges to market growth and widespread adoption. Innovations focusing on enhanced delivery systems, improved target specificity, and utilizing nanoparticles for safer and more effective RNAi delivery are promising areas for research and development. Companies should invest in merging RNAi with other gene-editing technologies like CRISPR to expand therapeutic applications and leverage partnerships with academic and research institutions to accelerate innovation and adoption in this dynamic market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Interference Technology Market

The RNA Interference Technology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Prevalence of Genetic and Chronic Disorders Globally
    • Increasing Application of RNAi Technology in Drug Discovery & Development
    • Growing Need for Molecular Diagnostics
  • Market Restraints
    • Stringent FDA Regulations Regarding RNAi Therapies
  • Market Opportunities
    • Ongoing Research and Development in the Field of Nanotechnology and Cancer
    • State-of-the-art RNAi Therapies in Development
  • Market Challenges
    • Concerns in Delivery of RNA-Interference Therapies

Porter's Five Forces: A Strategic Tool for Navigating the RNA Interference Technology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Interference Technology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Interference Technology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Interference Technology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Interference Technology Market

A detailed market share analysis in the RNA Interference Technology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Interference Technology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Interference Technology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Interference Technology Market, highlighting leading vendors and their innovative profiles. These include Gradalis, Inc., Arcturus Therapeutics Holdings Inc., Merck KGaA, NeuBase Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Novartis AG, Nutcracker Therapeutics, Inc., Bioneer Corporation, Ionis Pharmaceuticals, Inc., Arbutus Biopharma Corporation, AMSBIO, Atalanta Therapeutics, Phio Pharmaceuticals Corp., Thermo Fisher Scientific Inc., Sanofi S.A., AstraZeneca PLC, Dicerna Pharmaceuticals, Inc., Sirnaomics, Inc., ProQR Therapeutics N.V., Silence Therapeutics PLC, CureVac N.V., Alnylam Pharmaceuticals, Inc., and Gotham Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the RNA Interference Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across dsRNA, miRNA, and siRNA.
  • Based on Therapeutics, market is studied across Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders, Oncology, and Respiratory Disorders.
  • Based on Application, market is studied across Drug Discovery and Development and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Genetic and Chronic Disorders Globally
      • 5.1.1.2. Increasing Application of RNAi Technology in Drug Discovery & Development
      • 5.1.1.3. Growing Need for Molecular Diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent FDA Regulations Regarding RNAi Therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research and Development in the Field of Nanotechnology and Cancer
      • 5.1.3.2. State-of-the-art RNAi Therapies in Development
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns in Delivery of RNA-Interference Therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: siRNA's use for targeted gene therapy for treating a multitude of diseases
    • 5.2.2. Application: Exponential adoption of RNA interference technology for dru discovery & development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. RNA Interference Technology Market, by Type

  • 6.1. Introduction
  • 6.2. dsRNA
  • 6.3. miRNA
  • 6.4. siRNA

7. RNA Interference Technology Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Autoimmune Hepatitis
  • 7.3. Hepatitis B and C
  • 7.4. Neurological Disorders
  • 7.5. Oncology
  • 7.6. Respiratory Disorders

8. RNA Interference Technology Market, by Application

  • 8.1. Introduction
  • 8.2. Drug Discovery and Development
  • 8.3. Therapeutics

9. Americas RNA Interference Technology Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific RNA Interference Technology Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa RNA Interference Technology Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Switch Therapeutics Launches with USD 52 Million to Advance First-of-its-Kind RNAi Technology
    • 12.3.2. Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Companies Mentioned

  • 1. Gradalis, Inc.
  • 2. Arcturus Therapeutics Holdings Inc.
  • 3. Merck KGaA
  • 4. NeuBase Therapeutics, Inc.
  • 5. Arrowhead Pharmaceuticals, Inc.
  • 6. Novartis AG
  • 7. Nutcracker Therapeutics, Inc.
  • 8. Bioneer Corporation
  • 9. Ionis Pharmaceuticals, Inc.
  • 10. Arbutus Biopharma Corporation
  • 11. AMSBIO
  • 12. Atalanta Therapeutics
  • 13. Phio Pharmaceuticals Corp.
  • 14. Thermo Fisher Scientific Inc.
  • 15. Sanofi S.A.
  • 16. AstraZeneca PLC
  • 17. Dicerna Pharmaceuticals, Inc.
  • 18. Sirnaomics, Inc.
  • 19. ProQR Therapeutics N.V.
  • 20. Silence Therapeutics PLC
  • 21. CureVac N.V.
  • 22. Alnylam Pharmaceuticals, Inc.
  • 23. Gotham Therapeutics Corp.

LIST OF FIGURES

  • FIGURE 1. RNA INTERFERENCE TECHNOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RNA INTERFERENCE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RNA INTERFERENCE TECHNOLOGY MARKET DYNAMICS
  • TABLE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DSRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023